000166:SZSEShenwan Hongyuan Group Co., Ltd. Analysis
Data as of 2026-03-14 - not real-time
CN¥4.93
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Shenwan Hongyuan (000166.SZ) is trading at CNY 4.93, which sits below its 20‑day (4.98), 50‑day (5.12) and 200‑day (5.20) simple moving averages, indicating a short‑term bearish bias. The RSI of 44 points suggests the stock is not yet oversold, while the MACD line has just crossed above its signal line, delivering a modest bullish signal. Volume is accelerating and the 30‑day volatility of roughly 15 % remains moderate, supporting the view that price swings could be contained. On the valuation side, the trailing P/E of 13 is well under the industry average of 16, and the price‑to‑book of 1.11 is close to parity, implying the market may be discounting the stock. The consensus target price of around CNY 7.1 translates into an upside of more than 40 % from today’s level.
Fundamentally, the company posted a spectacular 76 % revenue growth and maintains healthy profit margins (gross 94 %, operating 71 %, net 29 %), yet operating cash flow is negative and the debt‑to‑equity ratio exceeds 260 %, flagging balance‑sheet pressure. Cash on hand (CNY 433 bn) exceeds total debt (CNY 367 bn), but the high leverage and weak cash generation raise questions about the sustainability of the 1.6 % dividend. The beta of roughly 0.2 indicates limited market‑wide volatility, while the increasing volume and low liquidity risk suggest the stock can be traded comfortably. Considering the “Greed” sentiment reading of 73 on the fear‑greed index, investors appear optimistic despite the bearish technical backdrop. Overall, the stock appears undervalued with strong upside potential, but the credit profile and cash‑flow weakness warrant caution.
Fundamentally, the company posted a spectacular 76 % revenue growth and maintains healthy profit margins (gross 94 %, operating 71 %, net 29 %), yet operating cash flow is negative and the debt‑to‑equity ratio exceeds 260 %, flagging balance‑sheet pressure. Cash on hand (CNY 433 bn) exceeds total debt (CNY 367 bn), but the high leverage and weak cash generation raise questions about the sustainability of the 1.6 % dividend. The beta of roughly 0.2 indicates limited market‑wide volatility, while the increasing volume and low liquidity risk suggest the stock can be traded comfortably. Considering the “Greed” sentiment reading of 73 on the fear‑greed index, investors appear optimistic despite the bearish technical backdrop. Overall, the stock appears undervalued with strong upside potential, but the credit profile and cash‑flow weakness warrant caution.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price below short‑term moving averages
- bullish MACD crossover
- large upside potential to target price
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- undervalued relative to peers (P/E 13 vs 16)
- robust revenue growth and margins
- target price implies >40% upside
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- high leverage and negative cash flow
- regulatory environment for Chinese capital‑market firms
- stable dividend yield but sustainability concerns
Key Metrics & Analysis
Financial Health
Revenue Growth75.90%
Profit Margin28.73%
P/E Ratio13.0
ROE7.62%
ROA1.48%
Debt/Equity263.05
P/B Ratio1.1
Op. Cash FlowCN¥-60881629184
Industry P/E16.4
Technical Analysis
TrendBearish
RSI43.7
SupportCN¥4.81
ResistanceCN¥5.13
MA 20CN¥4.98
MA 50CN¥5.12
MA 200CN¥5.20
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Target PriceCN¥7.16
Upside/Downside45.30%
GradeUndervalued
TypeGrowth
Dividend Yield1.64%
Risk Assessment
Beta0.21
Volatility15.29%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.